For us, one size never fits all in clinical trial development.

A niche provider of clinical research services, Catalyst Clinical Research offers clinical consulting services specializing in oncology product development through our Aptus Clinical solution. Designed to offer a truly creative and flexible service for clinical development projects, our bespoke clinical consulting supports first-in-human clinical development planning, from discovery through to the clinic, ensuring that new therapies reach patients as quickly and efficiently as possible, safely.

Clinical Research Consulting

Aptus, now part of Catalyst, is a leading clinical consultancy business which is designed to offer a truly creative and flexible solution for clinical development projects. Our focus is to deliver innovative technologies, collaborative and experienced staff, excellence and efficiency in delivery. We are committed to supporting new products and ensuring they start their development journey in an optimal position to reach the market and be the Catalyst to changing lives.

Catalyst are highly customer focused aiming to offer bespoke solutions from initial ad-hoc support right through to full-service CRO delivery should a client wish. We are able to offer scientific and industry experience in a collaborative approach by truly listening to our clients and supporting them to succeed.

How our consultancy works


Flexible consulting which is driven by you. This approach ideal for one-off activities with rapid timescales.

Project Driven

Enabling the Aptus' team to work with you on larger longer-term activities. Offering expertise and experience in a solution built to need and budget.

Flexible Resource

A flexible FTE approach, this allows a specialist to embed into your activities in a fully flexible manner to match your activities.

Examples of our solutions

Optimal design and execution of are critical for de-risking of clinical development programmes and achieving regulatory success.

  • Project Review, Gap Analysis and Recommendations - ½ day or 1 day workshop between Lead Optimisation and GLP Toxicology to review, Mechanism of Action, Target Selection, Pharmacology, Safety, Formulation, Dose Selection, Competitor Landscape, GLP Toxicology Plans, Target Patient Population etc. ​
  • Study Design Consulting​ - Target population selection, study design options, country and site selection, recruitment rates, landscape and competition evaluation, study duration, cost evaluation, study outline and protocol production etc.​
  • Regulatory Consultation​ - Regulatory Strategy, Competent Authority scientific advice, pre-IND meetings, ILAP strategy (MHRA), Acceleration/Protection strategy  (Orphan, Break-Through, Fast Track etc.)​
  • Medical writing - Protocol, PIL, Investigator Brochure, IMPD, CSR etc